Kaitanni (cadonilimab)

Cadonilimab-based chemotherapy with or without bevacizumab had a promising efficacy and manageable safety profile in the treatment of recurrent or metastatic gynecological malignancies.

P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital

P=N/A, N=31, Recruiting, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University o

P2, N=33, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

P2, N=38, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P2, N=20, Completed, Fujian Provincial Hospital; Fujian Provincial Hospital

P2, N=40, Recruiting, Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital

However, most signals derive from phase I/II single-arm or small-sample studies with limited follow-up, and no randomized head-to-head trials have yet confirmed superiority over standard PD-1+CTLA-4 approaches. This review summarizes the mechanism of action, structural characteristics, clinical research progress, and future applications of cadonilimab, with the aim of offering a useful reference for research and clinical treatment while promoting its broader application in oncology.

Cadonilimab might offer a promising option with a manageable safety profile for patients with R/M CC who progress after ICI treatment. Further studies with larger sample sizes are needed to confirm these findings.

Following nine cycles of cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, the patient achieved significant tumor regression and subsequent pathological complete response (pCR) after surgery, with a favorable safety profile observed throughout the treatment course. This case provides valuable clinical evidence supporting the efficacy and safety of cadonilimab in the neoadjuvant setting for dMMR/MSI-H colorectal cancer.

P1/2, N=63, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026

We used 131I-labeled cadonilimab (AK104), a PD-1/CTLA-4 tetravalent bispecific antibody, as a novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying therapeutic mechanism...The combination of 131I-based radiotherapy and bispecific ICIs remodels the TME and enhances the therapeutic efficacy in NSCLC. CD8+ T cell activation and neutrophil-mediated ROS and NO release are key mechanisms contributing to enhanced tumor cell killing.